Atlantic Healthcare ^Company

Gastrointestinal diseases, owns the worldwide rights to renzapride, a molecule, work also on orphan diseases. Currently developing differentiated, first-in-class treatments that leverage alicaforsen, an antisense therapeutic agent with a novel target for validated mechanism of action and the potential to treat multiple inflammatory GI diseases.